Manipulated Records and Cover Ups Delay FDA Approval for Bristol-Myers Drug


Jul 11, 2013


The pharmaceutical industry needs high-quality trials, but can they get them in low-cost areas?

According to documents posted the U.S. Food and Drug Administration, Bristol-Myers Squibb and Pfizer’s blood thinner, Eliquis, was stalled for nine months because of misconduct, errors and an alleged cover-up attempt at a Chinese trial site. FDA documents show that patients got the wrong medicine, records were secretly changed and “serious adverse events” went unreported. Read more

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments